SBIR Success Rates by Agency, Phase, and Applicant Type
SBIR Success Rates by Agency, Phase, and Applicant Type
When founders ask "what are my chances of winning an SBIR award?", the answer they usually get is a single percentage. The most authoritative version comes from the SBA: in its FY2022 SBIR/STTR Annual Report, SBA estimated a Phase I selection rate of 15% across all civilian agencies and 18% at DoD. That number is technically true and strategically misleading.
The single headline rate hides the four success rates that actually matter: Phase 1 win rate by agency and topic (which varies several-fold across agencies), Phase 1 to Phase 2 conversion (the more meaningful filter), long-term commercialization (the rate the program is ultimately judged on), and the first-time vs. repeat-applicant gap (the structural advantage that distorts everything else).
This article pulls together what publicly available SBIR data — from sbir.gov, SBA annual reports, NIH RePORT, GAO, National Academies (NASEM) program evaluations, and agency disclosures — tells us about each of these rates. Every figure below is linked to its source and dated. Rates move from year to year, so for a current decision, check the agency's latest data.
Key Takeaways
- The single "SBIR success rate" headline hides four rates: Phase 1 selection rate (an estimated 15% across civilian agencies and 18% at DoD in FY2022, per SBA), Phase 1-to-2 conversion (about 25% of NIH Phase 1 projects by 2016, per NASEM), commercialization (just under half of surveyed Phase 2 projects reported any sales in NASEM studies), and the first-time vs repeat applicant gap.
- Phase 1 selection rates vary several-fold: SBA's FY2022 estimates ranged from 6% (DOT, Education) to 22% (DHS) among civilian agencies, and from 9% (Army) to 27% (DARPA and the other defense agencies combined) within DoD. Topic-level variance within an agency is larger still.
- Rates also swing with funding: NIH's SBIR Phase 1 success rate fell from 15.7% in FY2023 to 7.8% in FY2025 as applications rose and awards fell.
- Award concentration is real but narrower than SBIR folklore suggests: 22 firms (under 1% of Phase 2 awardees) won 11% of Phase 2 awards in FY2011–2020 (GAO), while 39% of FY2022 Phase 1 winners were first-time winners (SBA).
- The pre-submission work (program officer call, topic alignment, customer discovery) is the part of the funnel an applicant controls; proposal polish can't fix a poor topic fit.
If you're planning an SBIR strategy and want a realistic understanding of what to expect from the funnel, the numbers below are the starting point.
What Are the Four SBIR Success Rates That Matter?
When SBIR success rate is quoted as a single percentage, it usually means "Phase 1 acceptance rate at the agency you applied to during the cycle you submitted." That's one rate. There are four:
-
Phase 1 win rate. The percentage of Phase 1 proposals funded. This varies by agency, by topic, by cycle, and by applicant type. SBA's FY2022 estimate across all civilian agencies was 15%; DoD's was 18% (SBA FY2022 Annual Report).
-
Phase 1 to Phase 2 conversion rate. Of Phase 1 projects, what share go on to a Phase 2 award. At NIH, the National Academies found this conversion rate fell from 31% to 25% between 2001 and 2016 (NASEM, 2022).
-
Long-term commercialization rate. Of Phase 2 projects, what share produce sales, licensing revenue, or follow-on contracts. In National Academies surveys, 49% of NIH Phase 2 projects (NASEM, 2015) and more than 45% of DoD Phase 2 projects (NASEM, 2014) reported at least some sales.
-
First-time vs. repeat applicant gap. Experienced SBIR firms have structural advantages over first-time applicants. This is the rate that distorts all the others, and the hardest one to find published.
Each rate is informative; together they describe the actual SBIR funnel, which is more demanding than the Phase 1 number alone suggests.
What Are SBIR Phase 1 Win Rates by Agency?
The headline Phase 1 win rate varies meaningfully across the eleven SBIR agencies. The most complete cross-agency snapshot is SBA's FY2022 SBIR/STTR Annual Report, which reports new Phase 1 proposals received and awards made for each agency. SBA labels these selection rates as estimates, because some FY2022 awards came from proposals received in FY2021. Where an agency publishes more recent figures, they're shown alongside.
| Agency | SBIR Phase 1 selection rate | Source and notes |
|---|---|---|
| NIH / HHS | 16% (FY2022, HHS); 15.7% (FY2023), 9.9% (FY2024), 7.8% (FY2025) at NIH | SBA FY2022 report; NIH RePORT Table 215. Rates vary by institute and center. |
| NSF | 11% (FY2022) | SBA FY2022 report. NSF says historical Phase 1 funding rates have been between 10% and 20%; full proposals require a Project Pitch invitation first. |
| DoD (all components) | 18% (FY2022) | SBA FY2022 report |
| Air Force | 17% (FY2022) | SBA FY2022 report; includes AFWERX Open Topic awards |
| Navy | 19% (FY2022) | SBA FY2022 report |
| Army | 9% (FY2022) | SBA FY2022 report |
| Other defense agencies (DARPA, MDA, SOCOM, DHA, OSD, and others, combined) | 27% (FY2022) | SBA FY2022 report; not broken out by agency |
| DOE | 19% (FY2022) | SBA FY2022 report |
| NASA | 19% (FY2022); 18.3% (2023), 18.6% (2024), 18.0% (2025) | SBA FY2022 report; NASA FY2026–2027 BAA Reference Guide |
| USDA | 15% (FY2022) | SBA FY2022 report |
| DHS, Commerce, EPA, DOT, Education | 22%, 11%, 16%, 6%, 6% (FY2022) | SBA FY2022 report; small applicant pools, so rates swing year to year |
Three observations that the table understates:
Topic-level variance is enormous. Within a given agency, individual topics can have very different competitive dynamics. As a hypothetical, a topic that receives 40 proposals and funds 4 has a 10% rate; a related topic in the same cycle that receives 3 proposals and funds 2 has a 67% rate. The headline agency average masks this.
Cycle effects. Phase 1 success rates move with appropriations and application volume. NIH is the clearest recent example: its SBIR Phase 1 success rate was 15.7% in FY2023, 9.9% in FY2024, and 7.8% in FY2025, as applications rose from 3,014 to 4,468 and awards fell from 472 to 349 (NIH RePORT).
Topic alignment dominates. A weak proposal on a hot topic still loses; a strong proposal on an off-topic submission still loses. In our experience, fit with the topic and the agency's priorities matters more than proposal polish. (See DoD SBIR Guide: Topics, TPOCs, and Winning Strategy for the topic-selection mechanics.)
What Is the Phase 1 to Phase 2 Conversion Rate?
Phase 1 to Phase 2 conversion is the more meaningful filter than Phase 1 itself, because Phase 2 is where the real R&D funding ($1M+) lives. Two rates matter at this stage.
Whether Phase 1 awardees apply for Phase 2. Not every Phase 1 awardee goes on to apply. Agencies don't routinely publish this rate, but the common reasons are well understood: the Phase 1 work showed the technology wasn't ready, the company pivoted away from the agency's interest, or the team disbanded during the Valley of Death gap.
Phase 2 selection rate (among applicants). Phase 2 proposals are funded at higher rates than Phase 1 proposals. SBA's FY2022 estimates were 32% at HHS, 36% at DOE, 49% at NSF, 45% at NASA, 50% at USDA, and 28% across DoD (SBA FY2022 Annual Report). NIH's regular SBIR Phase 2 success rate was 34.8% in FY2023 and 22.1% in FY2025 (NIH RePORT). The applicant pool is self-selected to companies whose Phase 1 work succeeded, and the agency has already invested in the project.
Net Phase 1-to-Phase 2 conversion. NIH has the best-documented figure: the National Academies found that the rate at which NIH Phase 1 projects converted to Phase 2 awards fell from 31% to 25% between 2001 and 2016 (NASEM, 2022). SBA also builds conversion into eligibility: companies with 21 or more Phase 1 awards over the past five fiscal years must keep a ratio of at least one Phase 2 award for every four Phase 1 awards (SBA performance benchmarks).
This rate matters because Phase 1 funding alone is rarely enough to fully commercialize a technology. A company that wins Phase 1 but never reaches Phase 2 has typically spent the Phase 1 award on feasibility work that the small business team can't follow through on at scale.
For the underlying phase mechanics, see SBIR Phase 1 vs 2 vs 3: A Stage-by-Stage Guide.
What Is the Long-Term Commercialization Rate?
The success rate that the SBIR program is ultimately judged on is whether Phase 2 awardees actually commercialize. This is the hardest rate to measure because "commercialization" has multiple definitions: commercial product sales, follow-on private investment, sole-source government contracts, IP licensing, acquisition by a larger company.
The most detailed evidence comes from the National Academies' agency-by-agency evaluations, which surveyed Phase 2 awardees:
- NIH: 49.2% of surveyed Phase 2 projects reported some sales, a further 24.9% expected sales, and 25.9% reported none and expected none (NASEM, 2015; projects from FY2001–2010).
- DoD: the share of Phase 2 projects reporting sales was "greater than 45 percent" (NASEM, 2014).
Two caveats. "Any sales" is a low bar, since a project with a single small contract counts. And survey respondents may skew toward companies that are still operating.
DoD's Phase 3 pathway is the largest by far. Phase 3 contracts use non-SBIR funds, and DoD reported $2.56 billion in Phase 3 obligations for FY2022, compared with about $21 million at HHS, $28 million at NASA, and $7 million at DOE (SBA FY2022 Annual Report). For defense-relevant technology, the government itself is often the first commercial customer.
NIH and NSF outcomes look different. Commercialization in these portfolios more often means clinical product launches, FDA clearances, licensing transactions with pharma or medtech companies, or private sales and follow-on investment. The timelines are also longer for biomedical products, where regulatory paths add years.
Patterns we see in practice (our observation, not a measured rate):
- Companies with prior SBIR experience tend to be better at turning awards into contracts and sales
- Phase 2 supplements that require matched investment (NIH Phase IIB programs, NSF Phase IIB, AFWERX STRATFI/TACFI) filter for projects that already have outside validation
- Teams that have done structured customer discovery (I-Corps or equivalent) write more credible commercialization plans
The implication: the headline Phase 1 rate is not the right thing to optimize for. The long-term commercialization outcome is. Designing an SBIR application around the commercialization plan rather than just the technical plan is the structural way to give your project a better shot at that outcome.
For the commercialization plan structure reviewers look for, see The SBIR Commercialization Plan: Template + 5 Examples.
How Big Is the First-Time vs. Repeat Applicant Gap?
The most consequential gap is between first-time SBIR applicants and companies with prior SBIR experience. Agencies don't publish separate success rates for the two groups, but the available evidence points in a consistent direction.
Experience is an advantage. Repeat applicants know how to write to the review criteria, engage the agency, and navigate the registrations, and program officers may already know their work. The National Academies' 2022 NIH assessment found that firms that won an award in their first year as NIH SBIR/STTR applicants went on to win more award dollars over time, with less time between awards, and suggested NIH do more to support first-time applicants (NASEM, 2022).
The "SBIR mill" pattern is real but narrower than folklore suggests. GAO found that 22 small businesses, fewer than 1% of the 6,865 Phase 2 awardees in FY2011–2020, received 11% of all Phase 2 awards and 10% of Phase 2 award dollars (GAO-24-106398, 2024). This concentration is what the benchmark requirements covered in our SBIR Eligibility guide are designed to address.
First-time winners are not rare. SBA reported that 39% of FY2022 Phase 1 SBIR/STTR award winners were first-time winners (SBA FY2022 Annual Report). At NIH, first-time applicants' share of annual awards rose from roughly 17% to 21% between 2012 and 2019, while the share going to multiple-award winners fell from 20% to 6% (NASEM, 2022).
Net implication for first-time applicants. Because the published agency average blends experienced and first-time applicants, a first-time applicant's realistic odds may be lower than the headline. No agency publishes that number, so treat the published average as optimistic rather than conservative.
The first SBIR application should be designed with realistic expectations: it's more likely to lose than to win, and the path to becoming a winner often includes one or more declined applications before a successful one.
The resubmission (A1 at NIH; similar mechanisms at other agencies) is structurally important precisely because of this. Many successful Phase 1 awardees were declined on their first attempt and funded on resubmission after addressing reviewer feedback. (See NIH SBIR Application Guide for the resubmission mechanics.)
Why Do Headline Rates Mislead First-Time Applicants?
Three structural reasons the headline SBIR success rate is misleading for first-time applicants:
1. The denominator is not uniform. Each cycle receives proposals that range from fully prepared to barely compliant, and some are returned without review. How each agency counts these differs, so the published rate is a blend that doesn't map neatly onto any one applicant's odds.
2. The numerator includes resubmissions and repeat winners. Resubmitted applications (NIH A1, equivalent at other agencies) and applications from experienced SBIR firms are baked into the success rate. A first-time, first-submission proposal is competing against that blend.
3. Topic alignment matters more than the average suggests. An on-topic, well-aligned proposal in an area the agency is actively funding faces much better odds than an off-topic or weakly aligned proposal, which may have almost no chance regardless of quality. The headline average smooths over this variance.
The realistic planning assumption for a first-time SBIR applicant: expect your odds on a first submission to be at or below your agency's published rate, plan for a resubmission, and put your effort into a topic genuinely aligned with the agency's priorities rather than one chosen for proposal convenience.
What Should the Numbers Tell You About SBIR Strategy?
Synthesizing all four rates into strategic implications:
Do the work that moves your odds. First-time applicants who do the pre-submission work (engaging program officers (NIH POs, DoD TPOCs), completing I-Corps (NSF), choosing topics carefully, building documented customer discovery) give reviewers more reasons to fund them. In our experience, the work done before submission matters more than the proposal text itself.
Apply to multiple agencies if eligible. With SBA's FY2022 Phase 1 selection rates at 15% for civilian agencies and 18% at DoD, roughly five out of six proposals were declined. Two submissions to different agencies double the work and nearly double the odds of at least one award. (The same work cannot be funded twice, so disclose overlapping submissions to each agency.)
Plan for resubmission. Treat the first submission as a learning round, not the only round. Many successful SBIR awardees were declined on their first attempt. Reviewer feedback is the single most valuable input for the resubmission, and addressing it substantively is required.
Don't conflate Phase 1 success with commercialization success. A Phase 1 award is a feasibility study, not a business. At NIH, only about a quarter of Phase 1 projects converted to Phase 2 by 2016, and in National Academies surveys roughly half of Phase 2 projects reported any sales at all. Optimize the application (and the company) for the long-term commercialization outcome, not just the Phase 1 win.
For the broader SBIR program structure and where each of these rates sits in the funnel, start with The Complete SBIR/STTR Guide.
Frequently Asked Questions
What is the average SBIR Phase 1 success rate?
SBA's FY2022 annual report estimated a Phase 1 selection rate of 15% across civilian agencies and 18% at DoD, with individual agencies ranging from 6% (DOT, Education) to 27% (DARPA and the other defense agencies combined). Rates change year to year: NIH's SBIR Phase 1 success rate fell from 15.7% in FY2023 to 7.8% in FY2025.
Are repeat SBIR winners more likely to win again?
Experienced SBIR firms have real advantages, and a small number of firms win many awards: GAO found 22 firms (under 1% of Phase 2 awardees) received 11% of Phase 2 awards in FY2011–2020. But first-time winners are common too; SBA reported that 39% of FY2022 Phase 1 winners were first-time winners. SBA's benchmark requirements apply additional performance standards to companies with many prior awards.
What percentage of Phase 1 awardees reach Phase 2?
At NIH, the National Academies found the Phase 1-to-Phase 2 conversion rate fell from 31% to 25% between 2001 and 2016. Among companies that do apply for Phase 2, selection rates are higher than for Phase 1: SBA's FY2022 estimates ran from 28% across DoD to 50% at USDA.
What is the long-term commercialization rate for SBIR awardees?
In National Academies surveys, 49% of NIH Phase 2 projects and more than 45% of DoD Phase 2 projects reported at least some sales. The definition of commercialization varies by agency: DoD tracks Phase 3 contracts (it reported $2.56 billion in Phase 3 obligations in FY2022), while NIH and NSF outcomes more often involve product launches, licensing, regulatory clearances, and follow-on investment.
Does an NSF Project Pitch invitation predict Phase 1 success?
An invitation means your idea fits the program, but it doesn't guarantee funding. The Project Pitch screens out poor-fit ideas before anyone writes a full proposal. Invited full proposals are then reviewed competitively; NSF says its historical Phase 1 funding rates have been between 10% and 20%.
How much does proposal quality affect success rates?
Substantially, but not as much as topic alignment. A median-quality proposal on a perfectly aligned topic can outperform a strong proposal on a poorly aligned topic. The pre-submission work (choosing the right topic, engaging the right program officer, demonstrating customer discovery) is what most reliably improves a proposal's odds.
Should I apply to multiple agencies in parallel?
If eligible, yes, with the caveat that the same work cannot be funded twice and overlapping submissions must be disclosed. Parallel applications increase the odds of an award while doubling the proposal-writing investment.
Ready to Move Into the Higher-Success-Rate Cohort?
SBIR success depends heavily on the pre-submission work (topic selection, program officer engagement, customer discovery, commercialization plan rigor), not just proposal polish. First-time applicants who do this work give themselves the best shot.
Commercify builds the commercialization-side foundation that strengthens an application — market analysis, competitive landscape, and customer discovery synthesis tailored to each agency's review criteria.
Move your SBIR application into the higher-rate cohort with Commercify →
Read next: The Complete SBIR/STTR Guide · The SBIR Commercialization Plan: Template + 5 Examples · SBIR Phase 1 vs 2 vs 3: A Stage-by-Stage Guide